BIO Announces Presenting Companies for 14th Annual BIO Investor Forum

Speakers Will Provide Fresh Insight, Investment Opportunities in Biotech Sector

Washington, D.C. (September 3, 2015) – The Biotechnology Industry Organization (BIO) today announced the initial list of presenting companies for the 14^th Annual BIO Investor Forum, an international investor forum which explores investment trends and opportunities in life sciences.  The event focuses on early and mid-stage private as well as emerging public companies that are poised for growth in 2016. The event will take place October 20-21, 2015, at the Parc 55 in San Francisco, California.

“We have a superb slate of over 100 companies signed up to present at this year’s BIO Investor Forum, and a global group of investors are lining up to hear from them,” said BIO President and CEO Jim Greenwood. “Based on current investor registration, we anticipate that attending investors’ assets under management and available funds will exceed all prior years, representing an excellent opportunity for companies looking for their next round of funding.”

Companies were chosen through a competitive screening process with input from BIO and the event’s advisory committee. The committee is comprised of members from top-tier firms focused on investing and banking in the life sciences industry in addition to executives from emerging and leading biotech and pharmaceutical companies.

The following companies are expected to present at the 14^th Annual BIO Investor Forum:

Private:

AbGenomics International Inc.
Adjuvance Technologies
Armetheon
ARMO BioSciences
Axikin Pharmaceuticals, Inc.
BioMarck Pharmaceuticals
C3 Jian, Inc.
Cantex Pharmaceuticals, Inc.
Comentis
Complexa
EnGeneIC Ltd.
Enterome
Helomics Corporation
ImmunGene, Inc.
Isarna Therapeutics
KineMed, Inc.
Kineta, Inc.
LA BioMed
Makindus, Inc.
MAX BioPharma
Protagonist Therapeutics Inc.
Protein Sciences
Rebiotix Inc
Relburn-Metabolomics, Inc.
Richcore Lifesciences
RuiYi
Savara
Silver Creek Pharmaceuticals, Inc.
Sutro Biopharma
Symic Biomedical
Thrasos Therapeutics Inc.
Thrombotargets Europe
True North Therapeutics, Inc.
Tyrogenex
ViaCyte
Xcovery
 

Public:

Amarantus BioScience Holdings, Inc.
AmpliPhi Biosciences
Apricus Biosciences, Inc.
Aptose Biosciences Inc.
Atossa Genetics Inc.
Aurinia Pharmaceuticals
Benitec Biopharma
Biocept
Bio-Path Holdings, Inc.
Catalyst Pharmaceuticals, Inc.
ContraFect
ContraVir Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc.
Critical Outcome Technologies Inc.
DelMar Pharmaceuticals, Inc.
Galmed Pharmaceuticals
GenSpera, Inc.
Helix Biopharma Corp.
Immunovaccine Inc.
Mast Therapeutics, Inc.
Matinas BioPharma Holdings, Inc.
Navidea Biopharmaceuticals
Neos Therapeutics
Newron Pharmaceuticals SpA
NovaBay Pharmaceuticals
Nuvo Research Inc.
Ocera Therapeutics, Inc.
Oncolytics
OncoSec Medical, Inc.
Opexa Therapeutics
Oxis International, Inc.
Palatin Technologies, Inc.
PCI Biotech
Probiodrug
Pulmatrix
Relmada Therapeutics
Relypsa
RepliCel Life Sciences Inc.
Resverlogix Corp.
Rexahn Pharmaceuticals
RXi Pharmaceuticals Corporation
Sophiris
Spectrum Pharmaceuticals
Synthetic Biologics, Inc.
Tokai Pharmaceuticals, Inc.
Viking Therapeutics, Inc.
Zafgen

Patient Advocacy/Non-Profit Organizations

The Leukemia & Lymphoma Society
The National MS Society/Fast Forward, LLC
Trade Office of Ecuador in Los Angeles

In addition, the 14^th Annual BIO Investor Forum will again host Discovery Track presentations, which focus on companies incorporated after 2010 that have raised less than $25M to date in seed or Series A financing rounds. Companies in this track are also first-time presenters and use biotechnology or related technologies for research and development of drug products or diagnostics. The following companies are scheduled to present in the Discovery Track:

AbVitro, Inc.
Aequor, Inc.
Agilis Biotherapeutics
AhR Pharmaceuticals, Inc.
Avelas Biosciences, Inc.
Avexegen Therapeutics
BioCurity Holdings, Inc.
Biomay AG
Capella Therapeutics, Inc.
Cardiavent, Inc.
CellSight Technologies
Codagenix, Inc.
Cormorant Pharmaceuticals
Crinetics Pharmaceuticals
Curza
Embera NeuroTherapeutics, Inc.
Euclises Pharmaceuticals, Inc.
Impel NeuroPharma
Magnus Life Science
Meryx, Inc.
MiNDERA Corp.
Monopar Therapeutics
MultiVir Inc.
Neovia Oncology Ltd
Oncoceutics, Inc.
Portal Instruments
Reltio
SolaranRx, Inc.
Susavion Biosciences, Inc.
Synergys Biotherapeutics, Inc.
Trigemina, Inc.
Valley Fever Solutions

New presenters are continuously being added. For updates on the list of presenting companies, please visit here. If you are interested in becoming a presenter, please submit an application here.

The BIO Investor Forum is the must-attend event for public and private market investors, research analysts, investment bankers, and industry executives focused on investment and business development opportunities in life sciences.  BIO One-on-One Partnering™ will also provide an opportunity to arrange meetings between investors; companies; and industry business development, licensing and therapeutic franchise heads.

BIO is pleased to recognize the leadership provided by the BIO Investor Forum Conference sponsors including our Regional Co-Hosts, BIOCOM and the California Life Sciences Association, as well as our Supporting Bank Sponsor, Roth Capital Partners. BIO Double Helix and Helix Sponsors include AbbVie, Amgen, Baxalta, Eli Lilly, Johnson & Johnson Innovation, Merck and Takeda Ventures. Conference sponsors include Aon Risk Solutions, Ash Stevens Inc., Bioscience Advisors, Blaise Group International, the Chubb Group of Insurance Companies, Clinical Network Services (CNS) PTY LTD, Fenwick & West LLP, FreeMind Group, Knobbe Martens, Morrison & Foerster LLP, NDA Group, Sichenzia Ross Friedman Ference LLP, Tiberend Strategic Advisors, Torreya Partners and VWR.

To learn more about the BIO Investor Forum, including registration and program information, please visit here. Registration is complimentary for credentialed members of the media and qualified investors.

Upcoming BIO Events